FindTrial
Sign In

Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody

DRUG4 trials

Sponsors

Hoffmann-La Roche

Conditions

Colorectal CancerTriple Negative Breast CancerTriple-Negative Breast CancerTriple-negative Breast Cancer

Phase 3

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
CompletedNCT02425891
Hoffmann-La RocheTriple Negative Breast Cancer
Start: 2015-06-23End: 2021-08-31Updated: 2022-07-19
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
CompletedNCT02788279
Hoffmann-La RocheColorectal Cancer
Start: 2016-07-05End: 2018-12-26Updated: 2019-12-11
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
CompletedNCT03125902
Hoffmann-La RocheTriple-Negative Breast Cancer
Start: 2017-08-25End: 2023-01-17Updated: 2024-03-26
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
CompletedNCT03197935
Hoffmann-La RocheTriple-negative Breast Cancer
Start: 2017-07-24End: 2022-09-28Updated: 2023-10-26

Related Papers

Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial
Nature Medicine2025-06-049 citations
Impact of proton pump inhibitor (PPI) pharmacogenomics (PGx) on toxicities associated with immune checkpoint inhibitor (ICI) therapy.
Journal of Clinical Oncology2025-05-28
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.
2025-05-098 citations
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Therapeutic Advances in Medical Oncology2025-01-0110 citations
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Clinical Cancer Research2023-12-0745 citations
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer
Nature Communications2023-09-2332 citations
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
Cancer Immunology Immunotherapy2023-06-0918 citations
Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.
2022-10-302 citations
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.
2022-09-1911 citations
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer
Communications Medicine2022-07-1518 citations
Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation: A comparative analysis of IMpassion130 and IMpassion131 peripheral blood mononuclear cells (PBMCs).
Journal of Clinical Oncology2022-06-014 citations
Mechanisms of action and acquired resistance to atezolizumab plus <i>nab</i>-paclitaxel in metastatic triple-negative breast cancer (mTNBC).
Journal of Clinical Oncology2022-06-012 citations
Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i>-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm
JCO Clinical Cancer Informatics2022-05-0111 citations
Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial
Cancer Research2022-02-159 citations
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
2021-07-01536 citations
Abstract LB162: Evaluation of tumor immune biomarkers with pathologic complete response (pCR) in patients receiving atezolizumab + chemotherapy in early triple negative breast cancer (eTNBC): exploratory analyses from the IMpassion031 study
Cancer Research2021-07-011 citations
The tumor microenvironment (TME) and atezolizumab + <i>nab</i>-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.
Journal of Clinical Oncology2021-05-2043 citations
Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Clinical Pharmacology in Drug Development2021-03-3122 citations
Abstract PD12-11: Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab + chemotherapy in early triple-negative breast cancer
Cancer Research2021-02-153 citations
Abstract GS3-02: Patient-reported outcomes (PROs) from the Ph 3 IMpassion031 trial of neoadjuvant (NA) atezolizumab + chemo in early triple-negative breast cancer (eTNBC)
Cancer Research2021-02-152 citations

22 more papers not shown